Goldman Sachs Group Inc.’s alternative investment arm has agreed to buy a majority stake in Dutch generic drugmaker Synthon from BC Partners.

BC Partners is nearing a deal to sell Dutch generic drugmaker Synthon International Holding BV to Goldman Sachs Asset ...

BC Partners has agreed to sell its majority stake in Synthon to Goldman Sachs Alternatives. Synthon is an international pharmaceutical company, with a platform specialized in developing, manufacturing ...

Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, according to people familiar with the matter, as it hopes to capitalise on demand for off ...

Goldman Sachs’ asset arm is in the process of acquiring the Dutch pharmaceutical company Synthon International for 2 billion ...

Buddy Chester LLC, an entity affiliated with private equity firm BC Partners, will commence a public offering of $500 million ...

Runway Growth Finance targets tech sector growth with a 15.4% yield. Learn why RWAY stock’s low Price/Book ratio makes it a ...

UK asset manager Arrow Global is poised to take over iQera Group as part of a debt overhaul agreed with the majority of its ...

Gross margin continues to be a focus for the company, and it saw a year-over-year improvement of 80 basis points to 29.3%. Chewy also continues to leverage its selling, general, and administrative (SG ...

Chewy Inc (NYSE:CHWY) shares are trading lower Thursday after the company announced a public offering by a selling stockholder and a concurrent share repurchase.

Innergex Renewable Energy Inc. (TSX: INE) ("Innergex" or the "Corporation") is proud to announce that three of its wind projects, co-developed with Indigenous partners, have been selected in BC ...